

## FOR IMMEDIATE RELEASE

### Theralase Starts Small Animal Cancer Therapy Trials

Toronto, Ontario – June 8, 2010 **Theralase Technologies Inc. (TSX-V: TLT)** announces it will commence Milestone 2 – small animal trials – of its research in its quest for cancer treatment.

Theralase advances towards commercializing light-activated photodynamic compounds for the destruction of cancer. Following successful Phase 1 approvals, Theralase has demonstrated positive results of pre-clinical study on its patented photodynamic compounds (PDC's) proving their ability to destroy cancerous cells, when light-activated with proprietary TLT laser technologies.

Dr. Lothar Lilge Ph.D, principal investigator and senior scientist at the Ontario Cancer Institute, Princess Margaret Hospital, states, "We are extremely pleased to be entering the next phase of our pre-clinical research with the patented Theralase photodynamic compounds in the destruction of small animal in-vivo cancers. This phase of the research will focus on the toxicity, safety and efficacy of the PDC's in a live small animal model. We will investigate the two lead compounds in the destruction of cancer cells, most notably focusing on breast and prostate cancer."

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. furthers, "We are excited to be working with such a world class group as Dr. Lilge and his entire team at the Ontario Cancer Institute at Princess Margaret Hospital and Dr. Karen Brewer and her team at Virginia Tech, who have originally designed and are further developing the photo dynamic compound technology that has the potential to make a major impact on a devastating disease."

Successful achievements in its current research will enable Theralase to commence Milestone 3, which is the treatment of cancer in cats and dogs. One in eight pet animals develop cancer in their lifetimes. This presents a significant opportunity for the Company.

The Theralase PDC research and development initiative is also jointly funded with the Ontario Centres of Excellence's (OCE's) Centre of Excellence for Photonics.

Visit the corporate or regulatory website at [www.theralase.com](http://www.theralase.com) or [www.sedar.com](http://www.sedar.com) for more information.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, and viruses. To learn more about Theralase, contact Roger Dumoulin-White, President and CEO of Theralase Technologies at 1 866 843 5273 or [rwhite@theralase.com](mailto:rwhite@theralase.com).

*This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.*